Prognostic scoring systems for patients with refractory/relapsed AML: GOELAMS score
| Factor . | Points . |
|---|---|
| CR1 duration | |
| ≥12 mo | 0 |
| ≤12 mo (refractory/early relapse) | 1 |
| FLT3-ITD status | |
| Negative | 0 |
| Positive | 1 |
| Cytogenetics* | |
| Favorable/intermediate | 0 |
| High risk | 1 |
| Factor . | Points . |
|---|---|
| CR1 duration | |
| ≥12 mo | 0 |
| ≤12 mo (refractory/early relapse) | 1 |
| FLT3-ITD status | |
| Negative | 0 |
| Positive | 1 |
| Cytogenetics* | |
| Favorable/intermediate | 0 |
| High risk | 1 |
For information on the GOELAMS score, see Chevallier et al.33 Prognostic groups: good (0 points; OS 58%, event-free survival [EFS] 45% at 2 y); intermediate (1 point; OS 37%, EFS 31% at 2 y); poor (2-3 points; OS 12%, EFS 12% at 2 y).
The cytogenetic risk group is defined according to MRC criteria.35